Patient and transplant characteristics of TA-TMA vs no TA-TMA in the SCD cohort
| . | TA-TMA (n = 7), n (%) . | No TA-TMA (n = 45), n (%) . | P value . |
|---|---|---|---|
| Sex∗ | .70 | ||
| Female | 3 (43) | 16 (35) | |
| Male | 4 (57) | 29 (65) | |
| Age, median (interquartile range), y† | 8 (12) | 8 (6) | .43 |
| SCD characteristics | |||
| Hydroxyurea use before HCT∗ | 7 (100) | 32 (71) | .12 |
| ≥3 vaso-occlusive crises before HCT∗ requiring admission | 3 (43) | 7 (9) | .12 |
| ≥1 acute chest syndrome before HCT∗ | 1 (14) | 2 (4) | .36 |
| Abnormal transcranial doppler∗ | 1 (14) | 10 (22) | .84 |
| Stroke∗ | 0 (0) | 4 (9) | .55 |
| Chronic transfusions∗ | 2 (29) | 12 (27) | .62 |
| Conditioning intensity∗ | .82 | ||
| Myeloablative | 6 (85) | 40 (89) | |
| Reduced intensity conditioning | 1 (15) | 5 (11) | |
| GVHD prophylaxis∗ | <.0001 | ||
| Calcineurin inhibitor | 5 (71) | 42 (93) | |
| Methotrexate | 4 (57) | 41 (91) | |
| Mycophenolate | 0 (0) | 0 (0) | |
| Sirolimus | 3 (43) | 3 (7) | |
| Posttransplant cyclophosphamide | 3 (43) | 3 (7) | |
| Abatacept | 1 (12) | 2 (4) | |
| αβ T-cell depletion | 0 (0) | 0 (0) | |
| HLA matching∗ | .04 | ||
| 10/10 MSD | 4 (57) | 42 (93) | |
| Haploidentical | 3 (42) | 3 (7) | |
| Stem cell source∗ | 1.0 | ||
| Bone marrow | 7 (100) | 44 (73) | |
| Bone marrow + UC | 0 (0) | 1 (22) | |
| VOD∗ | 0 (0) | 2 (4) | 1.0 |
| Reversible posterior encephalopathy syndrome∗ | 2 (29) | 1 (2) | .04 |
| Acute GVHD∗ | .01 | ||
| Grade 0 | 3 (42) | 40 (89) | |
| Grade 1-2 | 2 (29) | 3 (7) | |
| Grade 3-4 | 2 (29) | 2 (4) |
| . | TA-TMA (n = 7), n (%) . | No TA-TMA (n = 45), n (%) . | P value . |
|---|---|---|---|
| Sex∗ | .70 | ||
| Female | 3 (43) | 16 (35) | |
| Male | 4 (57) | 29 (65) | |
| Age, median (interquartile range), y† | 8 (12) | 8 (6) | .43 |
| SCD characteristics | |||
| Hydroxyurea use before HCT∗ | 7 (100) | 32 (71) | .12 |
| ≥3 vaso-occlusive crises before HCT∗ requiring admission | 3 (43) | 7 (9) | .12 |
| ≥1 acute chest syndrome before HCT∗ | 1 (14) | 2 (4) | .36 |
| Abnormal transcranial doppler∗ | 1 (14) | 10 (22) | .84 |
| Stroke∗ | 0 (0) | 4 (9) | .55 |
| Chronic transfusions∗ | 2 (29) | 12 (27) | .62 |
| Conditioning intensity∗ | .82 | ||
| Myeloablative | 6 (85) | 40 (89) | |
| Reduced intensity conditioning | 1 (15) | 5 (11) | |
| GVHD prophylaxis∗ | <.0001 | ||
| Calcineurin inhibitor | 5 (71) | 42 (93) | |
| Methotrexate | 4 (57) | 41 (91) | |
| Mycophenolate | 0 (0) | 0 (0) | |
| Sirolimus | 3 (43) | 3 (7) | |
| Posttransplant cyclophosphamide | 3 (43) | 3 (7) | |
| Abatacept | 1 (12) | 2 (4) | |
| αβ T-cell depletion | 0 (0) | 0 (0) | |
| HLA matching∗ | .04 | ||
| 10/10 MSD | 4 (57) | 42 (93) | |
| Haploidentical | 3 (42) | 3 (7) | |
| Stem cell source∗ | 1.0 | ||
| Bone marrow | 7 (100) | 44 (73) | |
| Bone marrow + UC | 0 (0) | 1 (22) | |
| VOD∗ | 0 (0) | 2 (4) | 1.0 |
| Reversible posterior encephalopathy syndrome∗ | 2 (29) | 1 (2) | .04 |
| Acute GVHD∗ | .01 | ||
| Grade 0 | 3 (42) | 40 (89) | |
| Grade 1-2 | 2 (29) | 3 (7) | |
| Grade 3-4 | 2 (29) | 2 (4) |